Page 96 - Read Online

Page 10 of 10 Papaluca et al. Hepatoma Res 2018;4:64 I http://dx.doi.org/10.20517/2394-5079.2018.53

www.bjs.gov/content/pub/pdf/mhppji.pdf. [Last accessed on 9 Oct 2018]
38. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA
practice. J Hepatol 2012;56:320-5.
39. Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent
Cancer 2016;11:24.
40. Leclerc P, Roy É, Morissette C. Le volet montréalais du Réseau SurvUDI: Volume 2: données au 30 juin 2008: agence de la santé et des
services sociaux de Montréal, direction de santé publique. Available from: http://collections.banq.qc.ca/ark:/52327/bs1983220. [Last
accessed on 12 Oct 2018]
41. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, et al. The present and future disease burden of hepatitis C virus (HCV) infection with
today’s treatment paradigm. J Viral Hepat 2014;21:34-59.
42. Browne AJ, Varcoe CM, Wong ST, Smye VL, Lavoie J, et al. Closing the health equity gap: evidence-based strategies for primary health
care organizations. Int J Equity Health 2012;11:59.
43. Hellard M, Sacks-Davis R, Doyle J. Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks. J
Epidemiol Community Health 2016;70:1151-4.
44. Rolls DA, Sacks-Davis R, Jenkinson R, McBryde E, Pattison P, et al. Hepatitis C transmission and treatment in contact networks of people
who inject drugs. PloS One 2013; doi: 10.1371/journal.pone.0078286.
45. Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann OM, Hansdottir I, et al. Treatment as prevention for hepatitis C (TraP Hep C) - a
nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med 2018;283:500-7.
46. Cousien A, Leclerc P, Morissette C, Bruneau J, Roy É, et al. The need for treatment scale-up to impact HCV transmission in people who
inject drugs in Montréal, Canada: a modelling study. BMC Infect Dis 2017;17:162.
47. Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject
drugs in the USA: a modelling study. Lancet Infect Dis 2018;18:215-24.
48. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic
evaluation. J Hepatol 2016;65:17-25.
49. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of
hepatitis C virus infection in the United States. Ann Intern Med 2015;163:215-23.
50. Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, et al. Modelling the impact of incarceration and prison-based hepatitis C virus
(HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction 2017;112:1302-14.
51. Martin NK, Vickerman P, Brew IF, Williamson J, Miners A, et al. Is increased hepatitis C virus case-finding combined with current or
8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology 2016;63:1796-
808.
52. Farley JD, Wong VK, Chung HV, Lim E, Walters G, et al. Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol
2005;19:153-6.
53. Sabbatani S, Giuliani R, Manfredi R. Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison
setting. Braz J Infect Dis 2006;10:274-8.
54. Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with
chronic hepatitis C. J Clin Gastroenterol 2009;43:686-91.
55. Strock P, Mossong J, Hawotte K, Arendt V. Access to treatment of hepatitis C in prison inmates. Dig Dis Sci 2009;54:1325-30.
56. Simonović Babić J, Bojović K, Delić D, Katanić N, Mitrović N, et al. Antiviral treatment of hepatitis C in Serbian prison setting: medical
treatment outcomes and patients’ adherence. Med Pregl 2016;69:85-91.
57. Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for
challenging treatment populations. Clin Infect Dis 2008;47:952-61.
58. Aspinall EJ, Mitchell W, Schofield J, Cairns A, Lamond S, et al. A matched comparison study of hepatitis C treatment outcomes in the
prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat 2016;23:1009-16.
59. Bartlett SR, Fox P, Cabatingan H, Jaros A, Gorton C, et al. Demonstration of near-elimination of hepatitis C virus among a prison
population: the Lotus Glen Correctional Centre hepatitis C treatment project. Clin Infect Dis 2018;67:460-3.
60. Blogg J, Wood J, McGrath C, Lobo C. Eradicating hepatitis C from the New South Wales prison system. Med J Aust 2018;208:276.
61. Sterling RK, Cherian R, Lewis S, Genther K, Driscoll C, et al. Treatment of HCV in the department of corrections in the era of oral
medications. J Correct Health Care 2018;24:127-36.
62. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current
injection drug users in Australia. Clin Infect Dis 2005;40:S313-20.